The James Buchanan Brady Urological Institute
  APPOINTMENTS: Johns Hopkins Hospital: 410-955-6100      Bayview Medical Center: 410-550-7008
Our kidney cancer program focuses on each patient as a unique individual. We aim to choose the best therapy through an experienced team of surgeons, medical oncologists, pathologists, and radiologists.

Diagnosed With Kidney Cancer

We understand the anxiety that a diagnosis of kidney cancer can bring to the patient and their family. The most important thing one can do is to learn about this disease and enlist the help of an experienced team of physicians.


Learn about Kidney Cancer

Clinical Trials

Johns Hopkins Studies

Research Endeavors
    The video clips may contain materials considered to be graphic and may not be suitable for all audiences.

    Click here to watch

Johns Hopkins Kidney Cancer Program

Diagnosed with Kidney Cancer?

We understand the anxiety that a diagnosis of kidney cancer can bring to the patient and their family.  The most important thing one can do is to learn about this disease and enlist the help of an experienced team of physicians. 

About 1/3 of kidney cancers are diagnosed
after the disease has spread to other organs. 

The first step is to obtain a "staging" evaluation to determine the extent of cancer.  This typically entails obtaining imaging of the chest, abdomen, and pelvis and comprehensive blood work.  Bone scans and evaluations of the brain are obtained depending on symptoms and the results of the initial studies. 

PET scans are rarely obtained due to their lack of sensitivity for detecting kidney cancer.


Kidney Tumor Contained within the Kidney

"Small" Kidney Tumor (<4cm)

Increasingly we are detecting these "small" kidney tumors due to the increased use of ultrasound, CT scan, and MRI.  Typically these are detected incidentally - in other words the patient has a scan for an unrelated problem and a tumor in the kidney is found.



It is important not to confuse a potential kidney cancer with a kidney cyst or other benign lesion.

Cysts are fluid filled structures that range from being "simple cysts" which are benign to more complex cysts which could be cancerous.  Cysts are graded on a scale from 1 to 4 (Bosniak Classification). 

Bosniak 1 and 2 lesions are likely to be benign whereas Bosniak 3 and 4 lesions are more likely to be cancerous.

What makes a growth on the kidney suspicious is when it appears to be solid on the imaging and when it "picks up" the dye that is used during CT or MRI scans (we call this enhancement).  Thus, it is important to have a good quality CT or MRI and have it read by a radiologist and urologist who are experts on kidney tumors.


kidney cancer  High quality "kidney mass protocol" CT scan showing a right kidney tumor.The intensity of the tumor is measured in different phases.  An increase of the Hounsfield Units (HU) of more than 20HU indicates that the mass is suspicious for cancer.  When the dye was given, this tumor went from 33HU to 85HU.  This patient underwent a robotic-assisted partial nephrectomy and the tumor was found to be a clear-cell kidney cancer.

About 20-30% of "suspicious" kidney tumors
when removed prove to be benign! 

These benign growths include cysts, oncocytomas, angiomyolipomas, and mixed epithelial stromal tumors.  Thus, 70-80% of these "small" kidney tumors are cancers and fortunately the majority are "well behaved" (low grade) cancers.  However, our studies reveal that about 1/3 of the cancers are aggressive.  Thus we take these tumors very seriously.


"What is an angiomyolipoma?"
 Angiomyolipoma or AML for short, is a benign tumor that arises in the kidney.  AMLs can bleed and while not cancerous are still taken very seriously.  "Angio" indicates blood vessels, "myo" indicates muscle, and "lipoma" indicates fat.  Thus, an AML is a tumor that contains these 3 components.  If one sees fat within the tumor on imaging, it is virtually diagnostic of this entity.  Since they are benign, AMLs can be observed in some patients.  If they are >4cm in size they are usually treated.  Treatment involves surgical resection (usually partial nephrectomy) or selective embolization.  Embolization is a procedure where the blood vessels feeding the AML are blocked without surgery.  This procedure shrinks the tumor and eliminates thus minimizing the risk of bleeding. 


"Who gets AMLS?"  AMLs are most common in females between the ages of 40-60.  Additionally, about 50% of patients with a syndrome called Tuberous Sclerosis will have AMLs.  Tuberous Sclerosis is a genetic disease associated with seizures, mental retardation, and a skin condition called adenoma sebaceum.


kidney cancer

A right kidney tumor with fat consistent with an angiomyolipoma, successfully treated with selective embolization.  Note how there is no blood flow to it after embolization.


"Should I get a biopsy?" - A question that we hear all the time.  There is a theoretical risk of bleeding or spreading the cancer with a biopsy, but this not why they are not widely used.

Unlike prostate, breast, or colon biopsies
it turns out that biopsies of small kidney tumors
are not as accurate as we would like. 

As many as 20% of the biopsies are "false negatives"-
in other words the biopsy says there is no cancer
when indeed there is a cancer. 

We still use them sometimes but it has to be in the right patient.  Recent innovations in how we do the biopsies has allowed us to get more information than ever before.  It remains, however, that a biopsy should only be obtained AFTER a discussion with an expert on this disease!

Treatment options for patients with a small kidney tumor including active surveillance, ablation, partial nephrectomy, and total nephrectomy.  In the vast majority of patients treatment of a small kidney tumor should result in saving the kidney.  A quick decision to remove the kidney may not be the best treatment.  Experience is critical in being able to save the kidney.  In our section regarding treatment one can find details regarding these options.

At Johns Hopkins our surgeons
are experts on all approaches
and will help tailor
the treatment to the patient. 
One size does NOT fit all.


Larger Kidney Tumors (>4cm)

As the tumor size increases, the likelihood it represents cancer increases as well.  Large oncocytomas, which are benign, are sometime impossible to distinguish from kidney cancer and thus there is still hope that a large kidney tumor is benign!  Prompt attention to these tumors is a must and a detailed evaluation is critical to making the best decision. 

    Questions to ask are:

         -Is there any evidence of spread?
         -Do the lymph nodes look enlarged?
         -Is the kidney vein clear of the tumor?
         -Is the adrenal gland involved?

A biopsy may be in order if the tumor looks atypical as there are rare mimickers of kidney cancer that would be treated differently. 

Three such scenarios are:

  1. Lymphomas where the treatment would be chemotherapy and not surgery
  2. Infections (abscess) where the treatment would be antibiotics and drainage
  3. Sarcoma where the treatment entails more than just surgical removal


kidney cancer
These are CT scans for two people found to have a left kidney tumor.  The patient on the left has a poorly defined mass (radiologists typically describe it as infiltrative) while the one has the right has a well defined solid tumor.  The tumor on the left was biopsied and found to be lymphoma.  The patient was treated with chemotherapy and did not need surgery.  The patient on the right had a robotic-assisted partial nephrectomy and was found to have a clear cell kidney cancer.)


Treatment options for these tumors include active surveillance, partial nephrectomy, and total nephrectomy.  Ablation is less attractive for larger tumors. In our section regarding treatment one can find details regarding these options. 

At Johns Hopkins our surgeons
are experts on all approaches
and will help tailor
the treatment to the patient. 
One size does NOT fit all.


Kidney Tumor with Suspicion of Spread

You may have been told that the kidney cancer has spread.  This could be to lymph nodes, the lungs, liver, bone, or even the vena cava—the largest vein in your body.  For tumors with vena cava involvement click here.

About 1/3 of patients find that the cancer
has spread even without any symptoms.

For those with symptoms, you may have experienced abdominal or back pain, blood in the urine, bone pain, seizures, or even bad headaches.  After a full evaluation of the extent of spread a treatment plan should be formulated. 

This can get quite complicated and a multidisciplinary team who specialize in kidney cancer would be best to help with this.  It is important that an urologist and medical oncologist collaborate in constructing an optimal plan for your care.  This multidisciplinary approach is most important for cancers with a high suspicion of spread!  This is because today there are NUMEROUS options and combinations for patients with metastatic kidney cancer. 

These options can include:

  1. Surgery -  In certain settings, removal of the kidney even when the cancer has already spread has been shown to improve survival.  This can often be done laparoscopically so the patient can recover rapidly and promptly receive additional therapy.
  2. Immunotherapy -  IL-2 (Interleukin-2) can be a good option for some patients and can deliver excellent results for some patients.  Interferon-alpha is another option.
  3. Targeted therapies -  These are more recent therapies that target biological pathways to help fight kidney cancer.   Examples are sunitinib, sorafenib, temsirolimus, bevacizumab, etc.
  4. Clinical trials -  Innovative trials with novel therapies are formulated on a regular basis.  Getting care at a center of excellence will increase your chances of finding out about these options.


There has never been a time when the options for metastatic kidney cancer were so numerous.  This can be confusing and requires a coordinated effort between you and your physicians to determine the best course of action.  Our medical oncologists are experts on the latest options.  They provide cutting edge care in a compassionate manner.

© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.| Disclaimer
Email: | 600 North Wolfe Street, Baltimore, Maryland 21287